Madrigal Pharmaceuticals, Inc. Director Stock Transactions

On August 1, 2025, Daniel J. Brennan, a director of Madrigal Pharmaceuticals, Inc., acquired 967 shares of common stock through restricted stock units (RSUs) and 1,705 shares through stock options. The RSUs vest in two equal installments on August 1, 2026, and August 1, 2027, contingent on Brennan's continued service with the company. The stock options vest 50% on the first anniversary of the grant date (August 1, 2026) and 12.5% every three months thereafter, also contingent on continued service. The stock options have an exercise price of $302.17 and expire on August 1, 2035. These transactions were reported in a Form 4 filing with the SEC.